Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 1.81B |
| Revenue (ttm) | 159.68M |
| Net Income (ttm) | -232.12M |
| Shares Out | 148.99M |
| EPS (ttm) | -1.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,684,173 |
| Open | 12.74 |
| Previous Close | 12.62 |
| Day's Range | 12.04 - 13.21 |
| 52-Week Range | 5.96 - 40.00 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 15.61 (+28.8%) |
| Earnings Date | Aug 3, 2022 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients wi... [Read more...]
Financial Performance
In 2021, ADPT's revenue was $154.34 million, an increase of 56.88% compared to the previous year's $98.38 million. Losses were -$207.28 million, 41.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 15.61, which is an increase of 28.80% from the latest price.
News
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 7.50% and 0.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...
Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?
Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in ...
clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: Should You Buy?
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022
SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Why Adaptive Biotechnologies Shares Are Rising
Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease. Adaptive Biotechnologies says, in...
Adaptive Biotechnologies launches T cell-based test for Lyme disease
Adaptive Biotechnologies unveiled a new type of test Wednesday for Lyme disease that may be most useful at detecting disease during the early stages of infection.
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests T-Detect Lyme enables patients and healthcare providers to detec...
Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Stand...
Data demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes Data demonstrate growing utilization of MRD to identify deep responses associated with th...
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
SEATTLE, May 26, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Lags Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies reports $38.6M in Q1 revenue as it repositions following job cuts
Adaptive Biotechnologies announced its first quarter earnings Wednesday, two months after laying off 12% of its workforce.
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...
Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...
Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste...
Cathie Wood Can't Get Enough of These 2 Biotech Stocks
The CEO of Ark Invest hasn't given up on these risky biotech stocks.
Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans
Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.
Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's MRD business includes clonoSEQ d...
Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to...
The company reiterates full year 2022 guidance The company reiterates full year 2022 guidance
Adaptive Biotechnologies lays off about 100 people, 12% of headcount, to ‘streamline our workforce'
Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned.
Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference
SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associa...
SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Adaptive Biotechnologies revenue rises 57% in 2021 to $154.3M
Adaptive Biotechnologies, which develops technology to assess the immune response, posted $154.